Latest Insider Transactions at Leap Therapeutics, Inc. (LPTX)
This section provides a real-time view of insider transactions for Leap Therapeutics, Inc. (LPTX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of LEAP THERAPEUTICS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of LEAP THERAPEUTICS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Mar 28
2025
|
Douglas E Onsi CEO,CFO,Pres.,GC,Treas.&Sec. |
BUY
Exercise of conversion of derivative security
|
Direct |
32,500
+23.44%
|
-
|
|
Mar 28
2025
|
Cynthia Sirard Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
22,500
+45.0%
|
-
|
|
Mar 28
2025
|
Christopher Mirabelli Chairman of the Board |
SELL
Payment of exercise price or tax liability
|
Direct |
6,672
-24.19%
|
$0
$0.32 P/Share
|
|
Mar 28
2025
|
Christopher Mirabelli Chairman of the Board |
BUY
Exercise of conversion of derivative security
|
Direct |
22,500
+44.92%
|
-
|
|
Mar 28
2025
|
John Mark O'Mahony Chief Manufacturing Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
22,500
+45.0%
|
-
|
|
Mar 28
2025
|
Augustine Lawlor Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,797
-28.26%
|
$0
$0.32 P/Share
|
|
Mar 28
2025
|
Augustine Lawlor Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
22,500
+44.92%
|
-
|
|
Mar 28
2025
|
Jason Baum Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,604
-29.35%
|
$0
$0.32 P/Share
|
|
Mar 28
2025
|
Jason Baum Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
22,500
+50.0%
|
-
|
|
Mar 28
2025
|
Christine Granfield VP, Head of Reg Affairs/Qual |
SELL
Payment of exercise price or tax liability
|
Direct |
6,604
-29.35%
|
$0
$0.32 P/Share
|
|
Mar 28
2025
|
Christine Granfield VP, Head of Reg Affairs/Qual |
BUY
Exercise of conversion of derivative security
|
Direct |
22,500
+50.0%
|
-
|
|
Nov 13
2024
|
Douglas E Onsi CEO,CFO,Pres.,GC,Treas.&Sec. |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
2,136
+0.31%
|
$4,272
$2.82 P/Share
|
|
Nov 13
2024
|
James H Cavanaugh Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
213
+50.0%
|
$426
$2.82 P/Share
|
|
Nov 13
2024
|
Christopher Mirabelli Chairman of the Board |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
2,136
+0.31%
|
$4,272
$2.82 P/Share
|
|
Nov 13
2024
|
Augustine Lawlor Chief Operating Officer |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
2,136
+0.31%
|
$4,272
$2.82 P/Share
|
|
Jan 26
2024
|
John Mark O'Mahony Chief Manufacturing Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
-
|
|
Jan 26
2024
|
Christopher Mirabelli Chairman of the Board |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+49.57%
|
-
|
|
Jan 26
2024
|
Douglas E Onsi CEO,CFO,Pres.,GC,Treas.&Sec. |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+9.24%
|
-
|
|
Jan 26
2024
|
Augustine Lawlor Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+49.57%
|
-
|
|
Jan 26
2024
|
Cynthia Sirard Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
-
|
|
Mar 17
2023
|
Douglas E Onsi CEO,CFO,Pres.,GC,Treas.&Sec. |
BUY
Exercise of conversion of derivative security
|
Direct |
660,606
+49.97%
|
-
|
|
Sep 24
2021
|
Bei Gene, Ltd. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
2,543,800
+25.72%
|
$5,087,600
$2.85 P/Share
|
|
Dec 28
2020
|
Health Care Ventures Viii, L.P. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
2,618,406
-100.0%
|
-
|
|
Jun 22
2020
|
Perceptive Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,750,000
+17.11%
|
$3,500,000
$2.0 P/Share
|